Skip to main content
SpringerLink
Log in

"Not only presidential candidates from Illinois" Haematology news from ASCO 2008

  • ASCO Update
  • Published:
memo - Magazine of European Medical Oncology Aims and scope Submit manuscript

Summary

At the haematological sessions of ASCO 2008 major progress was reported with regard to multiple aspects of haematologic neoplasia. Highlights included the emerging role of JAK2 inhibitors in CMPD, oxametaxine as a new treatment in CML and the differential management of TKIs in refractory or relapsing CML corresponding to mutational status and comorbidities. Demethylating agents increased their share in up-to-date treatment of myelodysplasia based on the followup of several Phase III studies. In multiple myeloma the 4-year landmark analysis of the ECOGE4A03 study further questioned the role of high dose therapy and autologous transplantation compared to Lenalidomide/low dose Dexamethasone induction therapy. Multiple new therapeutic antibodies (e.g. Lumiliximab) as well as better tolerated chemotherapeutics (e.g. Bendamustin) were the cornerstone of presentations in low-grade NHL and CLL. In general the reasonable refinement of targeted therapies is coming of age.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Mauro MJ, Baccarani M, Cervantes F, Lipton JH, Matloub Y, Sinha R, Stone RM. Dasatinib 2-year efficacy in patients with chronic-phase chronic myelogenous leukemia (CML-CP) with resistance or intolerance to imatinib (START-C). J Clin Oncol, 26(May 20 suppl): abstr 7009, 2008

    Google Scholar 

  • Rousselot H, Facon T, Paquette R, Bleickardt E, Dejardin D, Kantarjian HM. Dasatinib or high-dose imatinib for patients with chronic myelogenous leukemia chronic-phase (CML-CP) resistant to standard-dose imatinib: 2-year follow-up data from START-R. J Clin Oncol, 26(May 20 suppl): abstr 7012, 2008

    Google Scholar 

  • Benichou A, Khoury HJ, Corm S, Nicolini FE, Craig AR, Humphriss E, Cortes JE. Multicenter open label study of subcutaneous (SC) omacetaxine (OMA) in imatinib (IM)-resistant chronic myeloid leukemia (CML) patients (Pts) with the T315I mutation. J Clin Oncol, 26(May 20 suppl): abstr 7021, 2008

    Google Scholar 

  • Verstovsek S, Kantarjian HM, Pardanani A, Thomas DA, Cortes JE, Mesa R, Hogan W, Redman J, Levy R, Vaddi K, Tefferi A. A phase I/II study of INCB018424, an oral, selective JAK inhibitor, in patients with primary myelofibrosis (PMF) and post polycythemia vera/essential thrombocythemia myelofibrosis (Post-PV/ET MF). J Clin Oncol, 26(May 20 suppl): abstr 7004, 2008

  • Byrd JC, Castro JE, Flinn IW, Forero-Torres A, Kipps TJ, Heerema NA, Lin TS, Mu H, Tangri S, O'Brien S. Lumiliximab in combination with FCR for the treatment of relapsed chronic lymphocytic leukemia (CLL): results from a phase I/II multicenter study. J Clin Oncol, 26(May 20 suppl): abstr 7003, 2008

    Google Scholar 

  • Pathan N, Estrellado A, Ranuio J, O'Brien S, Kipps TJ, Cesano A, Mu H, Harris S, Tangri S. Correlation of clinical activity of lumiliximab in combination with FCR and ZAP 70 expression on B-cell chronic lymphocytic leukemia cells. J Clin Oncol, 26(May 20 suppl): abstr 7073, 2008

    Google Scholar 

  • Tan D, Rosenberg SA, Lavori P, Sigal BM, Levy R, Hoppe RT, Warnke R, Advani R, Natkunam Y, Plevritis SK, Horning SJ. Closing the gap: a comparison of observed versus expected survival in follicular lymphoma (FL) at Stanford University from 1960–2003. J Clin Oncol, 26(May 20 suppl): abstr 8535, 2008

  • Rummel MJ, Heine K, Bodenstein H, Baldus M, Stauch M, von Gruenhagen U, Banat A, Kaiser U. Efficacy and safety of bendamustine and rituximab in the treatment of indolent and mantle cell lymphomas in older patients. J Clin Oncol, 26(May 20 suppl): abstr 8572, 2008

    Google Scholar 

  • Pfreundschuh M, Zeynalova S, Poeschel V, Haenel M, Schmitz N, Ho AD, Reiser M, Loeffler M, Schubert J. Improved outcome of elderly patients with poor-prognosis diffuse large B-cell lymphoma (DLBCL) after dose-dense rituximab: results of the DENSE-R-CHOP-14 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). J Clin Oncol, 26(May 20 suppl): abstr 8508, 2008

  • Skikne BS, Ward MR, Nasser A, Aukerman L, Garcia-Manero G. A phase I, open-label, dose-escalation study to evaluate the safety, pharmacokinetics, and pharmacodynamics of oral azacitidine in subjects with myelodysplastic syndromes (MDS) or acute myelogenous leukemia (AML). J Clin Oncol, 26(May 20 suppl): abstr 7091, 2008

  • Walgren RA, Dao C, Kreisel F, Westervelt P, Abboud CN, Graubert T, Cashen AF, Uy GL, Gao F, Dipersio JF, Vij R. A phase II study of intravenous azacitidine alone in patients with myelodysplastic syndromes: NCT00384956. J Clin Oncol, 26(May 20 suppl): abstr 7097, 2008

    Google Scholar 

  • Steensma DP, Baer MR, Slack JL, Buckstein R, Godley LA, Larsen JS, Arora S, Cullen MT, Kantarjian HM. A multicenter phase II trial of the decitabine alternative 5-day dosing regimen: analysis of efficacy in various subgroups of patients with myelodysplastic syndromes (MDS). J Clin Oncol, 26(May 20 suppl): abstr 7032, 2008

  • Brandenburg NA, Weiss L, Bwire R, Schmidt M, Knight R, List AF. Venous thromboembolism in patients with myelodysplastic syndrome treated with lenalidomide: incidence and risk factors. J Clin Oncol, 26(May 20 suppl): abstr 7084, 2008

    Google Scholar 

  • Rajkumar SV, Jacobus S, Callander N, Fonseca R, Vesole D, Williams MV, Abonour R, Siegel DS, Katz M, Greipp PR. Randomized trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed myeloma (E4A03), a trial coordinated by the Eastern Cooperative Oncology Group: analysis of response, survival, and outcome with primary therapy and with stem cell transplantation. J Clin Oncol, 26(May 20 suppl): abstr 8504, 2008

    Google Scholar 

  • Palumbo AP, Falco P, Corradini P, Crippa C, Patriarca F, Rossini F, Offidani M, Liberati AM, Petrucci MT, Boccadoro M. Bortezomib, pegylated-lyposomal-doxorubicin and dexamethasone (PAD) as induction therapy prior to reduced intensity autologous stem cell transplant (ASCT) followed by lenalidomide and prednisone (LP) as consolidation and lenalidomide alone as maintenance. J Clin Oncol, 26(May 20 suppl): abstr 8518, 2008

  • Richardson PG, Lonial S, Jakubowiak A, Jagannath S, Raje N, Avigan D, Ghobrial IM, Knight R, Esseltine D, Anderson KC. Safety and efficacy of lenalidomide (Len), bortezomib (Bz), and dexamethasone (Dex) in patients (pts) with newly diagnosed multiple myeloma (MM): a phase I/II study. J Clin Oncol, 26(May 20 suppl): abstr 8520, 2008

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Innere Medizin V, Hämatologie & Onkologie, Universitätsklinik Innsbruck, Innsbruck, Austria

    W. Willenbacher

Authors
  1. W. Willenbacher
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to W. Willenbacher.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Willenbacher, W. "Not only presidential candidates from Illinois" Haematology news from ASCO 2008. memo 1, 277–279 (2008). https://doi.org/10.1007/s12254-008-0074-6

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12254-008-0074-6

Keywords

Search

Navigation